Key Points Novartis recently announced bad news for its Lp(a)-lowering drug, pelacarsen. Lilly is also developing a therapy for lowering Lp(a). However, Novartis' setback isn't anywhere close to a game changer for Lilly. 10 stocks we like better than Eli Lilly › Novartis (NYSE: NVS) just reported its third clinical failure in only seven days. One of the company's pipeline setbacks triggered a ripple impact throughout one of the most hotly anticipated drug races in the biopharmaceutical industry. Analysts are still trying to fully assess how much Novartis shook up the cardiovascular medicine space. But the world's largest healthcare company by market cap has found itself caught in the crossfire -- Eli Lilly (NYSE: LLY) . Missed Nvidia in 2009?
Nous affichons publiquement l'idee principale. Creez un compte gratuit pour lire l'article complet, l'enregistrer, le commenter et le relier au contexte marches et OSINT.